Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Research output: Contribution to journalArticlepeer-review

6 Citations (SciVal)

Fingerprint

Dive into the research topics of 'Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide'. Together they form a unique fingerprint.

Medicine & Life Sciences